$10.15
Price
$1.3B
Market Cap
—
P/E Ratio
-22.7
Forward P/E
$-0.37
EPS (TTM)
—
Dividend Yield
$195M
Cash
$1M
Total Debt
128M
Shares Out
$4.09
$14.39
52-Week Range
Institutional Ownership of TREVI THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Shares | Value | % of Portfolio | Cost Basis | Est. Return |
|---|---|---|---|---|---|
| No funds currently hold this stock. | |||||
Trading Activity for TREVI THERAPEUTICS INC
|
Fund / Manager
Click to search
|
Action | Change | Shares After | Value | Price |
|---|---|---|---|---|---|
| 2025-Q3 | |||||
| BUY | +232.4% | 5.1M | $47M | $7.42 | |
| 2025-Q2 | |||||
| SELL | -52.2% | 1.5M | $8M | $6.25 | |
| 2025-Q1 | |||||
| SELL | -26.6% | 3.2M | $20M | $4.29 | |
| 2022-Q3 | |||||
| BUY | NEW | 4.4M | $7M | $3.40 | |
Insider Trading for TREVI THERAPEUTICS INC
6 Months Insider Sentiment
Buy $0
Sell $0
0
Buys
0
Sells
+0
Net
0
Grants
Largest
$2K
Galletta
| Date |
Insider
Click to search
|
Role
Click to search
|
Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dec 02, 2025 | Christopher Galletta | Controller and Principal Accounting Officer | EXERCISE | 4.2K | $0.51 | $2K |